The Law Offices of Frank R. Cruz announces an investigation of Prestige Consumer Healthcare (“Prestige Consumer” or the “Company”) (NYSE: PBH) on behalf of investors concerning the Company’s possible violations of federal securities laws.

What Is The Investigation About?
On May 13, 2026, Prestige Consumer announced fourth quarter and full year 2026 earnings, including that, “for fiscal ’26, revenues decreased 4.5% organically versus the prior year” and “[t]otal company adjusted gross margin of 55.6% for the year was approximately flat to 55.8% in the prior year.”

In the associated earnings call, the Company’s CEO Ron Lombardi revealed “in Q4, Clear Eyes sales were below expectations due to delayed shipments and production shutdowns ahead of line updates.”

On this news, shares of Prestige Consumer fell $5.88 per share, or 11.35%, to close at $45.93 on May 14, 2026.